MedTrace Logo

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

NCT05006079 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-12-30

No results posted yet for this study

Summary

In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.

Conditions

  • Opioid Abuse
  • Benzodiazepine Abuse
  • Polysubstance Abuse

Interventions

DRUG

Morphine

immediate release oral 15mg dose

DRUG

Alprazolam

oral 0.25mg dose

DRUG

Placebo

Lactose

Sponsors & Collaborators

  • Henry Ford Health System

    collaborator OTHER

  • Wayne State University

    lead OTHER

Principal Investigators

  • Mark K Greenwald, PhD · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-13
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05006079 on ClinicalTrials.gov